Overview

NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye

Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
Study is to assess the safety and efficacy of NOVA22007 0.05% and 0.1% Cyclosporine Ophthalmic Cationic Emulsions QD compared to vehicle for the treatment of the signs and symptoms of dry eye after a 3 month treatment period.
Phase:
Phase 2
Details
Lead Sponsor:
Santen SAS
Treatments:
Cyclosporine
Cyclosporins